Enabling Subcutaneous Delivery Through Viscosity Optimization

Success Story: Enabling Subcutaneous Delivery Through Viscosity Optimization

Moving a biologic from intravenous infusion to subcutaneous injection almost always means raising the protein concentration, and viscosity rises steeply as it does. Left unresolved, that constrains device compatibility, injection force, manufacturability, and patient comfort.

Coriolis Pharma’s iterative, data-driven formulation development reduced viscosity by 40 to 50% on a high concentration product, without compromising stability or quality.

Download the success story below to see how the formulation strategy was built, tested, and confirmed in pre-filled syringes.

Facing High Concentration Challenges? Let’s Talk

Whether your current formulation stopped working on the way up, or you want to know how high the molecule can go before you commit material, our team is ready to help.